Eris Lifesciences Q1 FY26 results (Apr–Jun 2025) and concall

ERIS delivered a strong bottom-line performance in Q1 FY26, driven by margin expansion in the core Domestic Branded Business and the successfully integrated Biocon portfolio. While consolidated revenue growth was tempered by the intentional ramp-down of Trade Generics and temporary insulin supply shortages, the company is pivoting toward high-margin segments like GLP-1 and European CDMO opportunities. Management remains committed to significant deleveraging, targeting a Net Debt/EBITDA ratio of 1.5x by the end of FY26.